UCB, Inc. v. Mylan Technologies Inc., No. 21-2336 (Fed. Cir. Apr. 12, 2023)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

This appeal concerns the validity of U.S. Patent No. 10,130,589, directed to transdermal rotigotine patches and asserted by UCB, Inc., UCB Pharma GmbH, and LTH UCB, INC. v. ACTAVIS LABORATORIES UT, INC. 3 Lohman Therapie -Systeme AG (collectively, “UCB”) in Hatch-Waxman proceedings. UCB sued Actavis Laborato- ries UT, Inc. (“Actavis”) for infringement based on Actavis’s filing of an Abbreviated New Drug Application.